- #ADA26: Roche's incretin shot works in mid-stage trial in type 1 diabetesA daily incretin shot being developed by Roche has shown promise in type 1 diabetes — the form that is not generally believed to be directly treatable by GLP-1-based drugs. According to Phase 2 d…Endpoints · 1mo ago↗ source
- In Washington, biotech's China hawks are winning the conversationBiopharma industry lobby groups working to keep the pipeline open for plentiful, lower-cost drugs coming from China have awakened to the fact that they face a vocal opposition and a growing set of…Endpoints · 1mo ago↗ source
- Industry seeks more clarity on commissioner's voucher programThe pharma industry and rare disease advocates voiced concerns about the transparency and fairness of the Commissioner's National Priority Voucher pilot program. The program faces an uncertain fu…